SPY072
Rheumatoid Arthritis
Key Facts
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotech focused on redefining treatment for inflammatory bowel disease (IBD) and rheumatological conditions by engineering monoclonal antibodies with dramatically extended half-lives. The company's core strategy is to reduce the burden of frequent dosing, aiming for quarterly or twice-annual administration, while targeting validated pathways like α4β7, TL1A, and IL-23. With a multi-asset pipeline centered on the Phase 2 SKYLINE-UC trial and key data readouts expected throughout 2026, Spyre is positioning itself as a potential leader in next-generation, high-convenience biologic therapies.
View full company profileAbout Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotech focused on redefining treatment for inflammatory bowel disease (IBD) and rheumatological conditions by engineering monoclonal antibodies with dramatically extended half-lives. The company's core strategy is to reduce the burden of frequent dosing, aiming for quarterly or twice-annual administration, while targeting validated pathways like α4β7, TL1A, and IL-23. With a multi-asset pipeline centered on the Phase 2 SKYLINE-UC trial and key data readouts expected throughout 2026, Spyre is positioning itself as a potential leader in next-generation, high-convenience biologic therapies.
View full company profileAbout Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotech focused on redefining treatment for inflammatory bowel disease (IBD) and rheumatological conditions by engineering monoclonal antibodies with dramatically extended half-lives. The company's core strategy is to reduce the burden of frequent dosing, aiming for quarterly or twice-annual administration, while targeting validated pathways like α4β7, TL1A, and IL-23. With a multi-asset pipeline centered on the Phase 2 SKYLINE-UC trial and key data readouts expected throughout 2026, Spyre is positioning itself as a potential leader in next-generation, high-convenience biologic therapies.
View full company profileTherapeutic Areas
Other Rheumatoid Arthritis Drugs
| Drug | Company | Phase |
|---|---|---|
| Early Detection Test for Rheumatoid Arthritis | Age Labs | Development |
| Piclidenoson (CF101) | Can Fite Biopharma | Phase II/III |
| ERNA-201 | Eterna Therapeutics | Preclinical |
| Tc99m Tilmanocept | Navidea Biopharmaceuticals | Phase 2/3 |
| Monoclonal Antibody Biosimilar (Anti‑TNF) | USV Biologics Division | Phase 1 |
| Targeted Immunotherapy for Rheumatoid Arthritis (via Arthritis4Cure) | LFB | Pre-clinical |
| EYD-001 (Takinib analog) | EydisBio | Preclinical |
| LFD-200 | Lifordi Immunotherapeutics | Phase 1 |
| MEV-N01 | Mesenbio | Pre-clinical |
| CIT-013 | Citryll | Phase 2a |
| Restem-L | Restem | Phase 2 |
| ASIT Platform | Ahead Therapeutics | Pre-clinical |